Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 5/20 | 0.78 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899091 | 0.88 | TBXA2R (1.00) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL16627011 | 0.85 | TBXA2R (0.72) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL16625835 | 0.81 | DRD2 (0.60) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL16625833 | 0.79 | DRD2 (0.61) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL11921687 | 0.79 | DRD2 (0.61) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL1736272 | 0.75 | POLB (0.62) | TBXA2RKDM4EMAPT | |
| SCHEMBL13589712 | 0.73 | DRD2 (0.52) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL10348610 | 0.73 | DRD2 (0.78) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL16625824 | 0.71 | DRD2 (0.47) | TBXA2RDRD2DRD4MEN1KMT2A | |
| SCHEMBL11921686 | 0.71 | GAA (0.47) | TBXA2RDRD2DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | TBXA2R 2503/4885DRD2 2522/4885DRD4 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.